Information about Regorafenib

Generic Name : Regorafenib
Up-to-date prescription details regarding Regorafenib are provided here.

Understand it's uses, recommended dosages, its indications, how to take, when to take, when not to take, side effects, special precautions, warnings and its and its storage instructions.

You will also find a list of the medication's International and Indian brand or trade names, as well as its pricing information. For verification of the information presented on this page or for additional clarifications, it's advisable to consult your doctor.

Trade Names/Brand Names of Regorafenib

International :

Stivarga

Why is Regorafenib Prescribed? (Indications)

This medication is a kinase inhibitor, prescribed for metastatic colorectal cancer (CRC) in patients who have been previously treated with fluoropyrimidine- oxaliplatin-and irinotecan-based chemotherapy. It works by helping to stop cancer cells from growing.

What is the dosage of Regorafenib?

PO- The recommended dose is 160mg, once daily for the first 21 days of each 28-day cycle.

How should Regorafenib be taken?

It comes as a tablet to take by mouth with food.

What are the warnings and precautions for Regorafenib?

• Caution should be exercised in patients with history of bleeding problems, high blood pressure, heart, liver, or kidney diseases, any allergy, who are taking other medications, during pregnancy and breastfeeding.

• Avoid drinking grapefruit juice while taking this medication.

• Patient may develop with increased risk of Reversible Posterior Leukoencephalopathy Syndrome (RPLS). If it is so consult with your doctor immediately.

What are the side effects of Regorafenib?

Most Common- Weakness, fatigue, decreased appetite and food intake, Hand-foot skin reaction (HFSR) (palmar-plantar erythrodysesthesia [PPE]), diarrhea, weight loss, and infection.
General - Fever.
Metabolic - Anemia, weight loss.
Skin - Rash.
Gastrointestinal - Diarrhea.
Heart - High blood pressure, bleeding.
Respiratory - Difficulty in breathing.